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Abstract
Here we studied plasma metabolomic profiles as determinants of progression to ESRD in patients
with Type 2 diabetes (T2D). This nested case-control study evaluated 40 cases who progressed to
ESRD during 8-12 years of follow-up and 40 controls who remained alive without ESRD from the
Joslin Kidney Study cohort. Controls were matched with cases for baseline clinical characteristics;
although controls had slightly higher eGFR and lower levels of urinary albumin excretion than
T2D cases. Plasma metabolites at baseline were measured by mass spectrometry-based global
metabolomic profiling. Of the named metabolites in the library, 262 were detected in at least 80%
of the study patients. The metabolomic platform recognized 78 metabolites previously reported to
be elevated in ESRD (uremic solutes). Sixteen were already elevated in the baseline plasma of our
cases years before ESRD developed. Other uremic solutes were either not different or not
commonly detectable. Essential amino acids and their derivatives were significantly depleted in
the cases, whereas certain amino acid-derived acylcarnitines were increased. All findings
remained statistically significant after adjustment for differences between study groups in albumin
excretion rate, eGFR or HbA1c. Uremic solute differences were confirmed by quantitative
measurements. Thus, abnormal plasma concentrations of putative uremic solutes and essential
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tamino acids either contribute to progression to ESRD or are a manifestation of an early stage(s) of
the disease process that leads to ESRD in T2D.
INTRODUCTION
The incidence of End-Stage Renal Disease (ESRD) due to type 2 diabetes (T2D) increased
over the last 20 years despite improving hyperglycemia control and increased renoprotective
drugs use.(1) Clearly, a better understanding of the determinants responsible for progression
to ESRD in T2D is urgently needed if this “epidemic” is to be contained.
Recently developed platforms for global metabolomic profiling are capable of examining
hundreds of metabolites, so they are excellent tools to study complex metabolic alterations
associated with progression of diabetic nephropathy.(2, 3) Reliable metabolomic data can be
obtained with liquid or gas chromatography coupled with mass spectrometry (LC/GC-MS)
or NMR spectroscopy. Among those, MS – based platforms are the most sensitive.(2, 4-6)
One of the hallmarks of progression to ESRD is plasma accumulation of certain metabolites,
the so-called uremic solutes.(7-10) However, it is becoming apparent that increase in the
levels of uremic solutes in blood may be more than a simple reflection of impaired kidney
function.(11-13) The kidney is a key organ involved in the handling of major biochemical
classes of metabolites. Kidney function includes filtration of metabolites via glomeruli,
followed by their tubular secretion/reabsorption and synthesis/degradation in various
components of the renal parenchyma. At present it is unclear whether elevated levels of
uremic solutes precede or follow renal impairment. For example, elevated plasma
concentration of uremic solutes may contribute to glomerular as well as tubular damage in
diabetic nephropathy, and damage to those two components have been demonstrated in early
nephropathy.(14, 15) Various alterations of certain biochemical classes of metabolites
(amino acids, in particular) have been also reported in the associations with insulin
resistance, type 2 diabetes or chronic kidney injury per se.(16-19)
To date, few metabolomic studies focusing on diabetic nephropathy have been performed in
experimental models (20, 21) or in humans.(22-25) Nevertheless, the comparisons were
either cross-sectional or focused on albuminuria progression rather than on the kidney
failure, the ultimate outcome of the diabetic nephropathy.(22-25)
This study is the first that aims to survey the metabolomic profile of plasma in T2D subjects
with normal or mildly impaired renal function at baseline who developed ESRD during the
subsequent 8-12 years of follow-up. We aim to establish metabolomic profiles associated
with subsequent progression to ESRD in T2D so we may hypothesize about the underlying
mechanisms that initiate this progression.
RESULTS
Study groups and their characteristics
A cohort with T2D patients attending the Joslin Clinic was recruited into the Joslin Study of
the Genetics of Kidney Complications. Of the 509 patients examined between 1992 and
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t1996. 410 were followed until the end 2004. During 8-12 years of follow-up 59 (14.4%)
patients developed ESRD, 84 (20%) died without progressing to ESRD and 267 (65.1%)
remained alive without progressing to ESRD. Details of the follow-up study were already
published.(26)
For the present nested case-control study, we selected 40 patients who developed ESRD
(cases of progressors to ESRD) and matched them with 40 patients who were alive as of
2004 without ESRD (controls for non-progressors). Of the 80 patients, 75 identified
themselves as Caucasians of European origin. Baseline characteristics of the two selected
study groups are summarized in Table 1. The groups were very similar with regard to most
clinical characteristics. Progressors, however, had higher urinary albumin excretion and
slightly lower eGFR. Despite the differences noted in median AER and mean eGFR, there
was substantial overlap of the distributions in the two study groups. At baseline the majority
of progressors and non-progressors were in CKD stage 2. CKD stage 3 was present in 7% of
controls and 22% of cases, respectively. Overall the distribution of CKD stages was not
statistically different between the study groups. 87% of non-progressors had annual eGFR
decrease less than 3.5 ml/min/1.73m2. The median (25th, 75th percentile) decrease was −1.95
(−3.2, −0.8) ml/min/1.73m2 and the slope was determined based on the serial creatinine
measurements over 7.6 (6.5-12.4) years. The study groups did not also differ regarding
baseline plasma levels of parathormone.
Results of global metabolomic analysis
Baseline plasma samples from study subjects were run on the Metabolon platform against a
library containing mass spectra for 2400 chemically identified metabolites. A total of 445
named metabolites were detected. Of these, 183 belonged to drug-related metabolites or had
low detectability and were excluded from further analysis. The remaining 262 were detected
in at least 80% of the study subjects so we designate them as “common.” We repeated the
assay in the follow-up plasma sample taken one to three years later for a subgroup of study
patients to estimate intra-individual variation for each metabolite. The results by
biochemical classes are summarized in Figure 1 and presented in details in supplemental
Table 1. A rank correlation coefficient ≥0.4 between these paired samples was used to
distinguish metabolites with persistent or transient concentrations. By this criterion, 119 of
the common metabolites (45%) tracked well over time within individual and thus were
considered persistent, defined here as “stable” and of particular interest, which remains in
accordance with the systematic report by Floegel et al. (27)
Fold differences between the mean plasma concentration in progressors to ESRD and non-
progressors were analyzed for the 262 common metabolites (Table 2). In the analysis of fold
difference, 49 (19%) were significant after adjusting for multiple comparisons (q value
<0.05). Among the subset of 119 metabolites stable over time, 28 (23%) differed
significantly from 1.0. These results are summarized in Table 2 according to biochemical
class and whether the metabolite has been identified as a uremic solute. The proportion of
metabolites associated with ESRD progression was similar regardless of whether the
metabolite was stable over time. Nevertheless, we focused further analysis on the stable ones
because their involvement in a prolonged process such as progression to ESRD is more
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tplausible. Among the biochemical classes, the proportion associated with ESRD was high
for amino acids and their derivatives, carbohydrates, and modified nucleotides (40%, 42%,
and 57%, respectively), intermediate (16%) for other metabolites, and low (4%) for lipids
(see Supplemental Figure 1A-1D).
Progression to ESRD according to plasma concentration of uremic solutes
The fold difference between progressors and non-progressors and its q value for each of
these metabolites are plotted in Figure 2A according to whether the metabolite has been
identified as a uremic solute. Among 119 metabolites that were common and stable over
time within individual, 18 are known as uremic solutes and, of these, the fold difference was
significantly increased above 1.0 for 12 (67%). To obtain a descriptive measure of their
effects on the risk of progression to ESRD, we turned to logistic regression analysis so we
can express the associations in terms of odds ratios for the outcome, ESRD. The results are
grouped by biochemical class in Figure 3, which also shows the odds ratios after adjustment
for the clinical covariates, AER, eGFR and HbA1c. The fact that the associations remained
after adjustment for AER, eGFR and HbA1c suggests that the effects of these uremic solutes
are potentially independent from the clinical characteristics.
Among the amino acid-derived uremic solutes associated with progression to ESRD were
two, p-cresol sulfate and phenylacetylglutamine, produced by the gut microbiome. Their
effects on the risk of progression to ESRD were strong. For example, the odds ratio for
progression to ESRD for a one standard deviation increase in plasma p-cresol sulfate
concentration was 2.3 (95%CI; 1.3, 3.9) in univariable analysis. The effect of
phenylacetylglutamine was similar, but slightly less than that of p-cresol sulfate. Of the six
polyol derived uremic solutes significantly associated with the risk of progression to ESRD,
myo-inositol was the one most strongly associated, odds ratio: 3.2 (95% CI; 1.7, 5.9). Of the
four nucleotide-derived uremic solutes significantly associated with the risk of progression
to ESRD, three are derived from degradation of RNA and the fourth (urate or uric acid) is
derived from degradation of DNA. The strongest association with progression to ESRD was
for pseudouridine, odds ratio 7.8 (95% CI; 3.1, 19).
Progression to ESRD according to plasma concentration of amino acids and their
derivatives
Thirty-nine metabolites representing amino acids or their derivatives were common and
stable over time and 14 of them (29%) were associated with risk of progression to ESRD.
The fold difference between progressors and non-progressors and its q-value for each of
these metabolites are plotted in Figure 2B along with other common and stable metabolites
after removal of the 16 uremic solutes (including 2 amino acid derivatives).
The effects of the remaining 12 amino acids on risk of ESRD were estimated with logistic
regression Figure 4. In addition, five essential amino acids are present, although they were
not stable over time. As in Figure 3, the odds ratios after adjustment for the group
differences in AER, eGFR and HbA1c are also shown. It is important to note that none of
the associations in Figure 4 were diminished by the adjustments, therefore they seem to be
independent of these clinical covariates. In contrast to the associations with uremic solutes,
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tconcentrations of many of these metabolites were higher in the non-progressors than the
progressors. For example, low concentrations of six essential proteogenic amino acids were
associated with progression to ESRD. The odds ratio for progression to ESRD for a one
standard deviation increase in the plasma concentration of leucine was 0.5 (95% CI; 0.3,
0.8) and odds ratios for the remaining 5 amino acids were similar Figure 4. In addition, five
amino acid derivatives were negatively associated with risk of progression to ESRD. The
odds ratio for a one standard deviation increase in plasma concentration of 2-
hydroxyisocaproate (leucine derivative) was 0.3 (95%CI; 0.2, 0.6), and the odds ratios for
the remaining five derivatives were similar.
A few amino acid derivatives were positively associated with progression to ESRD. C-
glycosyltryptophan was elevated and the most significantly different between progressors
and non-progressors among the metabolites shown in Figure 2B. The odds ratio for a one
standard deviation increase in its plasma concentration was 6.6 (95%CI; 2.8, 15). The five
remaining metabolites, which are derivatives related to acylcarnitines and the urea cycle,
were positively associated with progression to ESRD with smaller odds ratios.
Among other metabolites associated with ESRD risk, there were two lipids, dihomo-
linolenate (20:3n3) and docosapentaenoate (n3 DPA; 22:5n3). Both are ω6 fatty acids and
were negatively associated with risk of progression to ESRD. Gluconate and two
metabolites involved in vitamin B metabolism: pantothenate and N1-methyl-2-pyridone-5-
carboxamide were positively associated with progression to ESRD. Data for these five
metabolites were not shown.
Reduction of redundant data
Among metabolites significantly associated with progression to ESRD, some may reflect on
shared underlying biology. To evaluate the potential redundancy among these metabolites,
we created a Spearman rank correlation matrix. Approximately two-thirds of the metabolites
were strongly correlated (data not shown).
A cluster analysis revealed clusters (see Figure 5) mirroring the patterns of our grouping
based on the biological relevance presented in Figures 3 and 4, respectively.(28, 29) Clusters
1 and 2 comprised uremic solutes and C-glycosyltryptophan. Cluster 3 included carnitine
derivatives, urate and urea. Cluster 4 comprised essential amino acids, cluster 5 their keto-
and cluster 6 their hydroxylderivatives, respectively. In a logistic regression model including
the leading metabolites from each cluster, erythritol, glutaryl carnitine and
alphahydroxyisovalerate (from clusters 2, 3 and 6) remained significant. Odds ratios for an
effect of one standard deviation difference in those metabolites considered together were:
for erythritol 2.1 (95% CI 1.0, 4.5), for glutaroyl carnitine, 2.6 (95% CI 1.3, 5.4) and for 2-
hydroxyisovalerate, 0.4 (95% CI 0.2, 0.9), respectively. Discrimination ability was c=0.89
for this model, while it was 0.74 to 0.75 for models including the significant metabolites
separately. The p value for the difference tested by integrated discrimination improvement
(IDI) test was p<0.001 for each single model in comparison with the model including all
four metabolites. When either pseudouridine or C-glycosyltryptophan (the most significantly
different metabolites between the progressors and non-progressors present in Cluster 2) were
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remaining metabolites became borderline or non-significant.
Targeted quantitative metabolites measurements
To validate our findings, we performed targeted quantitative measurements of nine common
and stable metabolites over time identified on the Metabolon global biochemical profiling
platform. Five out of nine metabolites were the ones strongly associated with progression to
ESRD. Among the remaining four, two metabolites, indoxyl sulfate and hippurate were
uremic solutes reported in the literature, but not significantly associated with progression in
the global profiling study. The remaining two measured were allantoin and uracil, linked in
the metabolic pathways related to urate and pseudouridine, respectively. Allantoin was not
sufficiently detectable by our quantitative methods (data not shown). For each of the other
metabolites, association with progression to ESRD was consistent with the result obtained
via global profiling. Also the association remained after adjustment for AER, eGFR and
HbA1c (Table 3). Odds ratio for ESRD progression was 1.7 (95%CI; 1.0, 2.8) per one
standard deviation of the logarithmically transformed metabolite, p-cresol sulfate and
phenylacetylglutamine and higher than 2.5 for every other significant metabolite
(pseudouridine, p-cresol sulfate, myoinositol and urate). We confirmed that hippurate and
indoxyl sulfate were not significantly associated with ESRD in our study. Logistic
regression of the pseudouridine/uracil ratio did not improve the discrimination ability of the
model (data not shown).
DISCUSSION
This study was performed in subjects with T2D, the majority of whom had normal renal
function at baseline. Half progressed to ESRD and half did not during a decade of follow-up.
In baseline plasma, progressors could be distinguished from non-progressors by high
concentrations of metabolites referred to as uremic solutes and low concentrations of certain
amino acids and their derivatives. This is the first demonstration that abnormal plasma
concentrations of certain metabolites are associated with risk of progression to ESRD at a
very early stage of diabetic nephropathy.
Uremic solutes, as catalogued by EUTox group,(7, 9) comprise compounds of different
biochemical classes: amino acid derivatives, certain alcohol/polyols and modified
nucleosides among them. Of the 18 known uremic solutes that were detected as common
and stable metabolites with the Metabolon platform, 12 were elevated in subjects who
progressed to ESRD. On the basis of results of multiple cross-sectional studies (7-10) the
immediate interpretation of our findings might be that the increased concentration of uremic
solutes was due to significant impairment of renal function in subjects who progressed to
ESRD during 8-12 years of follow-up. However, the majority of progressors at baseline
were in CKD stages 1 and 2 and had only slightly lower baseline eGFR than non-
progressors (75±19 ml/min vs. 87 ±23ml/min). In multivariable analyses, the odds ratios of
progression to ESRD for specific uremic solutes were only minimally affected by
adjustment for eGFR, AER and HbA1c. In the following we discuss each sub-group of
uremic solutes associated with risk of ESRD.
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tPhenyl compounds, such as p-cresol sulfate and phenylacetylglutamine are the most
extensively studied solutes known to increase in the uremic state.(8, 11, 13) These solutes
can be toxic to endothelial cells and can contribute to increased risk of cardiovascular
complications in patients with renal impairment.(30, 31) In humans these metabolites are
exogenous and are produced by intestinal bacterial flora before they are absorbed into
plasma and excreted through the kidney.(8, 11, 13, 32) Evidence confirming the microbiome
as a source for these solutes was recently provided in a study of ESRD subjects with and
without a colon.(11) In our study, high plasma concentrations of these solutes were
associated with progression to ESRD. It would be valuable to determine how different or
similar those concentrations are in comparison with subjects at competing risk of subsequent
cardiovascular complications.(33)
Three additional solute derivatives of amino acids that are synthesized in the gut, phenol
sulfate, indoleacetate and 3-indoxyl sulfate, were elevated in plasma of progressors
compared to non-progressors, however, the differences did not reach statistical significance
(see supplemental Table 2). All these findings support the notion that the gut microbiome
(11, 13, 32) might control plasma levels of amino acid-derived uremic solutes, and their high
levels increase the risk of progression to ESRD in subjects with T2D. The increase in
circulating levels of these solutes also may be attributed to dietary factors.(34)
Elevated plasma concentrations of myo-inositol and other polyols were strongly associated
with progression to ESRD in our study. These metabolites accumulate in plasma in the
uremia state and during acute kidney injury.(9, 35, 36) The kidney is the most important
organ for whole body metabolism of myo-inositol, as both the synthetic and degradative
enzymes, L-myo-inositol-1-phosphate synthetase and myo-inositol oxygenase (MIOX), are
highly expressed in the renal parenchyma.(37, 38) Myo-inositol can be obtained also from
dietary sources. Regulation of its plasma levels is complex, involving glomerular filtration,
reabsorption in proximal tubules in competition with glucose transport, apparent conversion
to chiro-inositol in tissues and, finally, catabolic degradation of myo-inositol by MIOX, a
protein that is upregulated by hyperglycemia.(36, 38-44) The high concentration gradients of
myo-inositol in certain tissues such as kidney and the vascular endothelium are maintained
by the osmoregulatory sodium/myo-inositol cotransporter 1 (SMIT1)(39, 40) Glucose/myo-
inositol imbalance was demonstrated to induce proliferative and pro-fibrotic response in the
proximal tubules in vitro and to alter the immune responses in leukocytes.(45, 46) Increased
urinary excretion of myo-inositol and inositol imbalance in muscle tissue (high myo/chiro-
inositol ratios) were reported in subjects with T2D.(42-44) In our study chiroinositol levels
were hardly detectable (data not shown).
Plasma concentrations of several nucleotide derivatives that are considered to be uremic
solutes were also strongly associated with progression to ESRD in our study. Among these
derivatives, elevated concentration of pseudouridine in plasma was the strongest and most
statistically significant predictor of progression. Pseudouridine belongs to the group of
modified nucleosides that are regarded as indicators of whole-body RNA turnover.(47)
These metabolites are increased in patients with malignancies,(48) and with uremia.(8,
49-51) Pseudouridine is synthesized from uracil(52, 53) and constitutes an end product, as it
is not catabolized in humans.(54) Trace study in humans with radiolabeled pseudouridine
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tshowed that the kidney handling includes glomerular filtration and also tubular reabsorption.
(55) High plasma levels of two other pyrimidine derivatives that are closely correlated with
plasma levels of pseudouridine also increased the risk of ESRD progression (N2, N2-
dimethylguanosine, and N4-acetylcytidine). These three nucleotides increase in plasma as
urinary excretion decreases and accumulate significantly in the uremic state.(51)
Urate (uric acid) is a metabolite of purine metabolism. In our study, increased plasma
concentrations were associated with progression to ESRD. Urate is another compound
known to accumulate in the uremic state.(8, 9) Its increase, however, is disproportionally
small due to compensatory mechanisms including increased enteric excretion, decreased
production(56) and possibly altered tubular handling.(57) In our recent study, elevated
plasma level of urate was a strong predictor of early renal function decline during follow-up
of a large cohort of subjects with T1D.(58)
What are the mechanisms through which the elevated plasma levels of uremic solutes
identified in our study could increase risk of progression to ESRD? The common feature of
these organic solutes is that all are handled by the tubular compartment. Uremic toxins
(including indoxyl sulfate and uric acid) have been reported to cause proximal tubular injury
via different mechanisms, tubulointerstitial hypoxia, endoplasmic reticulum stress or via
organic anion transporters (OAT)-mediated mechanisms (59, 60 61). Increase in the urinary
excretion of indoxyl sulfate predicted albuminuria development in Pima Indian subjects with
T2D and normal renal function at baseline.(63) The SLC22 family of transporters comprises
OATs, urate transporters and organic carnitine transporters. Numerous family members are
expressed in the proximal tubules on either basolateral or apical side. Their function was
extensively reviewed recently.(61, 62) OAT knockout animals accumulate uremic solutes in
plasma(62), whereas decreased expression of certain basolateral organic transporters has
been identified in chronic kidney failure.(63, 64) Hippurate is an interesting example of a
uremic solute that is not a uremic toxin. It is one of the most highly accumulated metabolites
in ESRD, the concentrations are up to 100 times that in normal subjects.(9-11) However, in
vitro, hippurate does not demonstrate an OAT-dependent toxic effect.(65) Our study groups
had preserved renal function and baseline hippurate levels did not differ between cases and
controls.
Kidney protein turnover, as compared with muscle and splanchnic turnover, is characterized
by the highest rates of protein synthesis and amino acid oxidation, mainly in the
tubulointerstitium.(17, 66) Depletion of the circulating pools of branched chain amino acids
and tryptophan are known phenomena accompanying advanced chronic kidney disease.(10,
16, 17) On the other hand, increase in those amino acids was shown to predict development
of T2D. (19) Interestingly, our study revealed that not only branched and aromatic, but also
all other essential amino acids and their derivatives were lower in subjects who progressed
to ESRD than in those who were non-progressors. In an experimental model of acute kidney
injury, one of the strongest metabolic responses to nephrotoxins was massive excretion of all
essential amino acids.(35, 67) It needs to be determined whether impaired tubular
reabsorption contributes to the decreased levels of amino acids in early diabetic
nephropathy. Amino acids that were decreased in subjects at risk of ESRD in our study all
have a neutral charge. They are handled by the B0AT1 cotransporter responsible for the
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tluminal influx, the heterodimeric exchanger and the facilitated diffusion transporter TAT1 in
charge of the basolateral efflux and possibly by other transporters.(68, 69)
Among amino-acid derivatives, one C-glycosyltryptophan showed a different pattern of
association than the others. Its plasma concentration was the highest in progressors when
compared with non-progressors. After pseudouridine it had the second highest fold
difference between the study groups. Plasma concentrations of both were very highly
correlated. Interestingly, they both carry a C-glycosylation linkage, a rare type of
posttranslational protein modification.(70) The biological meaning of this mutual
characteristic remains unknown. Increased expression of the proteins containing certain
forms of C-glycosylated tryptophan in the aortic vessels have been reported in the diabetic
rats.(71) C-glycosylated tryptophan also correlates with eGFR.(72)
Analysis of acylcarnitines revealed that the increased concentrations were independently
associated with risk of progression to ESRD. Acylcarnitines are filtered through the kidney
and about 75% are excreted into urine.(73) Serum acylcarnitines deriving from lipid and
amino acids are inversely correlated with GFR in individuals with normal as well as with
impaired renal function.(18, 74, 75) Acylcarnitines transport is regulated by organic
carnitine transporters in the kidney.(61) It is interesting also that in our study amino acid-
deriving (but not lipid-deriving) acylcarnitines were increased in the subjects at risk. They
are generated via beta-oxidation of the branched chain amino acids. Those amino acids and
their intermediate keto acid derivatives were also depleted in our study (2-oxoisoleucine, 2-
oxoisocaproate), which may suggest an enhanced mitochondrial amino acids beta-oxidation.
Strengths and limitations of our study should be considered. In contrast to multiple case-
control studies previously reported, ours is the first follow-up study in which progressors
and non-progressors were studied at the time when the majority had normal renal function.
We used the most comprehensive metabolomics platform with the broadest spectrum of the
metabolites examined. We acknowledge that the study groups were small and that, although
the prevailing majority was of homogenous ancestry origin, not all the study subjects were
of the same ancestry. Therefore our findings, which are exploratory in nature, warrant
replication study. Nevertheless, the differences between the study groups were statistically
significant when individual metabolites or grouped-metabolites were compared. Traditional
pathway analysis was not performed because more than half of the common metabolites
observed in this study are not yet among those with universal pathway database annotations
(52, 53).
STUDY GROUPS AND METHODS
Study group
Between 1991 and 1995, a cohort with T2D was recruited into the Joslin Study of the
Genetics of Type 2 Diabetes and Kidney Complications (half with normoalbuminuria and
half with microalbuminuria or proteinuria). The cohort was followed-up until 2004 for the
occurrence of ESRD or death unrelated to ESRD. Details of the recruitment, examination,
and follow-up of this cohort were already published elsewhere.(26) Among 410 individuals,
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t59 developed ESRD and 84 died without ESRD as ascertained by United States Renal Data
System(1), National Death Index(76) and medical records review.
For this nested case-control study, 40 out of 56 incident cases of ESRD who had sufficient
stored plasma samples at baseline available were selected. A group of 40 subjects from
among those who survived and were without ESRD as of the end of follow-up were selected
as controls. They were grouped-matched with cases with regard to gender, age, and baseline
eGFR. For comparison of cases and controls we used baseline clinical characteristics as
reported previously.(26)
As a small reproducibility study, ten study subjects (balanced by caseness status) had plasma
samples selected 2.2+0.8 years after baseline. All plasma samples were stored at −70°C until
analysis. The study protocol and informed consent procedures were approved by the Joslin
Diabetes Center Institutional Review Board.
Global metabolomics profiling
All plasma samples (80 baseline and 10 from the early follow up timepoint) were subjected
to global metabolomic profiling (Metabolon, Inc, Durham, NC). (5, 6) The detailed
protocols of global metabolomics profiling are provided in the Supplementary information.
Uremic solutes
The European Uremic Toxins (EUTox) Work Group, initiated in 1999, consists of 24
European Research Institutes and provides the most comprehensive encyclopedic list of
systematically and critically reviewed uremic solutes/toxins.(7, 9) Metabolites measured
with the global profiling were classified as uremic solutes/toxins based on the EUTox list
prepared in 2003, revisited in 2012 as well as based on selected relevant other publications.
(7-9, 11, 13, 32) Seventy eight uremic solutes are available in the Metabolon library. For
detailed information of the detectable uremic solutes in our study, please see Supplemental
Table 2.
Targeted quantitative measurements of metabolites—Method description of the
quantitative methods is provided in the Supplementary information.
Data analysis
Differences in clinical characteristics between the two study groups were tested by analysis
of variance for continuous variables and chi-square test for categorical variables.
Preliminary data cleaning included investigations of detectability, batch effects and outliers
at the metabolite- and individual-levels (heatmap, principal component procedures; data not
shown).(29, 77) Volcano plots were generated for common metabolites based on the fold
difference between the outcome groups and the p-value obtained in a general linear model.
Adjustment for multiple comparison was performed with a positive false discovery rate
(pFDR) q value <0.05 for significance.(78) The effect of a metabolite was estimated using
logistic regression. After transformation of the metabolite concentration to normally
distributed ranks, its effect on risk of progression was expressed as the odds ratio for a one
standard deviation difference.(26) Clinical covariates and metabolites measured
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tquantitatively were transformed to their (base 10) logarithms for the logistic analysis. Non-
common metabolites were analyzed as categorical variables by chi-square, but this analysis
did not result in identifying additional significant metabolites (data not shown).
Correlations between the continuous variables were examined with Spearman rank
correlation. Data reduction was carried out with hierarchical cluster analysis using the Ward
method based on values transformed to normally distributed ranks. Top metabolites from the
multivariate volcano plots analysis were included. More than a half of the detected
metabolites lacked pathway identifiers, preventing us from a comprehensive canonical
pathway analysis. Data analysis was performed with SAS 9.3 and JMP Pro 9.0.0 softwares
(Cary, NC).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Stability of the common metabolites within individual in subjects with type 2 diabetes in
plasma samples taken 1-2 years apart.
Footnote: Spearman rank correlation coefficients ( r ) are presented per individual
measurements. Blue line and number represents median value per a specific class.
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Multivariate analysis (volcano plot) of all common metabolites measured on the Metabolon
platform and their association with progression to ESRD are demonstrated as a fold
difference (x axis) and significance adjusted for multiple comparisons and presented as q
values (y axis). Uremic solutes comprise metabolites of interests in Figure 2A, amino acids
are metabolites of interests in Figure 2B. Uremic solutes are not displayed in Figure 2B.
Common and stable metabolites of interest are represented as red circles ( ), common, but
not stable over time as red empty circles ( ), all other common as grey circles ( ). Blue
circles represent essential amino acids ( ).
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tFigure 3.
Logistic regression analysis of the effect of the plasma concentration of metabolites
identified as uremic solutes on the risk of progression to ESRD in patients with T2D.
Footnote: Data are odds ratios and 95% confidence intervals (OR, 95% CI) estimated for an
effect of one standard deviation change of the metabolite. Abbreviations: ESRD – end stage
renal disease, T2D – type 2 diabetes, HbA1c – hemoglobin A1c, AER – albumin excretion
rate, eGFR – estimated glomerular filtration rate.
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Logistic regression analysis of the effect of the plasma concentration of proteogenic amino
acids and amino acid derivatives on the risk of progression to ESRD in subjects with T2D.
Footnote: Data are odds ratios and 95% confidence intervals (OR, 95% CI) estimated for an
effect of one standard deviation change of the metabolite. * Metabolite was not stable over
time but is shown for its biological relevance. Abbreviations: ESRD – end stage renal
disease, T2D – type 2 diabetes,HbA1c – hemoglobin A1c, AER – albumin excretion rate,
eGFR – estimated glomerular filtration rate, OR – odds ratio.
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Hierarchical cluster analysis (Ward's method) of the metabolites significantly associated
with progression to ESRD. Separate clusters are marked in different colors. Distance scale is
shown. Footnote: C1-C6 represent respective clusters.
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